This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 2 of 3 for:    ALZT OP1

Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease (COGNITE)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by AZTherapies, Inc.
Sponsor:
Collaborators:
PharmaConsulting Group
KCAS Bio
APCER Life Sciences
Information provided by (Responsible Party):
AZTherapies, Inc.
ClinicalTrials.gov Identifier:
NCT02547818
First received: September 10, 2015
Last updated: June 23, 2017
Last verified: June 2017
  Purpose
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).

Condition Intervention Phase
Alzheimer's Disease Drug: ALZT-OP1a Drug: ALZT-OP1b Other: Placebo ALZT-OP1a Other: Placebo ALZT-OP1b Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by AZTherapies, Inc.:

Primary Outcome Measures:
  • Clinical Dementia Rating-Sum of Boxes (CDR-SB) [ Time Frame: Baseline and Week 72 ]
    The combination active treatment group will be compared to each of the single component groups, including the placebo group, the mean change from Baseline to Week 72 will be quantified.


Secondary Outcome Measures:
  • Number of Treatment Emergent Adverse Events (TEAE) [ Time Frame: 72 weeks ]
    Safety will be evaluated based on the number, type, and frequency of treatment emergent adverse events. They will be individually presented for all subjects in data listings, and summarized in tables by treatment group and by treatment assignment. The AE's will be summarized and reported collectively based on information obtained through physical examination, ECG, and laboratory findings captured after dosing is initiated.


Estimated Enrollment: 600
Study Start Date: September 2015
Estimated Study Completion Date: March 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group I
ALZT-OP1a active capsules for inhalation and ALZT-OP1b placebo capsules for oral administration.
Drug: ALZT-OP1a
AB polymerization inhibitor
Other Name: Cromolyn
Other: Placebo ALZT-OP1b
Non-active tablets
Active Comparator: Group II
ALZT-OP1a active capsules for inhalation and ALZT-OP1b active tablets for oral administration.
Drug: ALZT-OP1a
AB polymerization inhibitor
Other Name: Cromolyn
Drug: ALZT-OP1b
Anti-inflammatory
Other Name: Ibuprofen
Active Comparator: Group III
ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b active tablets for oral administration.
Drug: ALZT-OP1b
Anti-inflammatory
Other Name: Ibuprofen
Other: Placebo ALZT-OP1a
Non-active capsules
Placebo Comparator: Group IV
ALZT-OP1a placebo capsules for inhalation and ALZT-OP1b placebo tablets for oral administration.
Other: Placebo ALZT-OP1a
Non-active capsules
Other: Placebo ALZT-OP1b
Non-active tablets

Detailed Description:

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Subjects will be randomly assigned to one of four treatment arms: Group I will consist of ALZT-OP1a (cromolyn) for inhalation, plus an oral placebo tablet; OR the Group II arm, which will consist of ALZT-OP1 combination therapy ALZT-OP1a (cromolyn) for inhalation, plus ALZT-OP1b (ibuprofen) tablet for oral administration; OR to the Group III arm, which will consist of inhaled placebo, plus ALZT-OP1b (ibuprofen) tablet for oral administration; OR to the Group IV placebo arm, which will consist of inhaled placebo plus an oral placebo tablet.

A minimum of 400 evaluable subjects will be randomized to receive one of four possible treatment assignments containing various combinations of active study drug or placebo.

To account for subject dropouts (estimated rate of 30%), it is anticipated that up to 600 (or 150 subjects per treatment arm) may be recruited and randomized, to achieve a minimum of 100 evaluable subjects per treatment arm.

  Eligibility

Ages Eligible for Study:   55 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 55-79 years old;
  • ≥ 8 years of education;
  • Study partner is available who has frequent contact with the participant (e.g. an average of 10 hours per week or more), and can accompany the participant to all clinic visits for the duration of the protocol;
  • Evidence of early AD, as defined by all of the following:

    1. Memory complaint by subject or study partner that is verified by a study partner;
    2. Objective memory impairment for age, documented by scoring below the education adjusted cutoff of the Logical Memory II subscale (Delayed Paragraph Recall) from the Wechsler Memory Scale Third Edition (the maximum score is 25):

      • ≤ 8 for 16 or more years of education, or
      • ≤ 4 for 8-15 years of education;
      • Essentially preserved general cognitive function;
      • Largely intact functional activities;
      • Not demented;
  • Cerebrospinal fluid (CSF) biomarker results consistent with early AD, including CSF Aβ-42 levels ≥ 180 pg/mL and ≤ 690 pg/mL;
  • Clinical Dementia Rating (Global) = 0.5; Memory Box score must be at least 0.5;
  • Must be fluent in the language of the cognitive testing material being administered;
  • Stability of permitted medications for 4 weeks prior to study start; subjects receiving acetylcholinesterase inhibitors and/or memantine should be on stable dose of those medications for at least 12 weeks prior to study start with every effort to maintain stable dose for the duration of the study;
  • Visual and auditory acuity adequate for neuropsychological testing;
  • Good general health with no diseases expected to interfere with the study;
  • Must provide written informed consent for APOe4 genotype testing;
  • Must provide written informed consent for CSF sampling.

Exclusion Criteria:

  • Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities;
  • Major depressive episode, as described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) within the past 6 months, which could lead to difficulty complying with the protocol;
  • History of schizophrenia or bipolar disorder (DSM-IV criteria);
  • History of alcohol or substance abuse or dependence within the past 3 years (DSM-IV criteria);
  • Currently taking medications that could lead to difficulty complying with the protocol; subjects must be on a stable dose of current medications for 4 weeks prior to study entry, with the exception of acetylcholinesterase inhibitors and/or memantine, which must be on a stable dose for at least 12 weeks prior to study entry;
  • Investigational agents are prohibited one month prior to entry and for the duration of the trial;
  • Currently taking medications known to be CYP2C9 inducers (i.e. carbamazepine and rifampicin);
  • Currently taking cromolyn, or have taken cromolyn, within the past 12 months;
  • Chronic daily use of high-dose NSAID for osteoarthritis, rheumatoid arthritis, or other chronic inflammatory diseases ("chronic" defined as 3200 mg/day for >2 weeks);
  • Chronic daily use of aspirin exceeding standard of care guidelines for low dose aspirin therapy for prevention of stroke and/or other recommended uses;
  • Allergy to cromolyn (also known as Intal®, Nasalcrom®, Opticrom®, Gastrocrom®, etc.);
  • Allergies to ibuprofen (Advil®, Motrin®, Nuprin®, etc.) or aspirin;
  • Clinically significant respiratory disorders with impaired respiratory effort or difficulty taking inhaled drugs;
  • Uncontrolled chronic asthma;
  • Abnormal pulmonary function test, defined for this protocol as: FEV1/FVC < predicted value for subject AND FEV1 < 70% of predicted value, indicating moderate or severe respiratory obstruction;
  • Taking inhaled protein products on a chronic basis;
  • Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol;
  • Pregnancy or lactation for female subjects of child-bearing potential (i.e., < two years post-menopausal or not surgically sterile);
  • For sexually active male subjects, unwillingness or incapability of using appropriate contraception methods;
  • Severe renal or hepatic impairment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02547818

Contacts
Contact: David A. Brazier, BS 617-318-3428 david.brazier@aztherapies.com
Contact: David R. Elmaleh, PhD delmaleh@aztherapies.com

  Show 80 Study Locations
Sponsors and Collaborators
AZTherapies, Inc.
PharmaConsulting Group
KCAS Bio
APCER Life Sciences
Investigators
Study Director: David R. Elmaleh, PhD AZTherapies, Inc.
  More Information

Additional Information:
Responsible Party: AZTherapies, Inc.
ClinicalTrials.gov Identifier: NCT02547818     History of Changes
Other Study ID Numbers: AZT-001
Study First Received: September 10, 2015
Last Updated: June 23, 2017

Keywords provided by AZTherapies, Inc.:
Early stage AD
MCI
aMCI
prodromal
Memory loss
Memory problems
Aging
Early Alzheimer's Disease
Early AD

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 23, 2017